-
Tytuł:
-
Management of HIV-2 resistance to antiretroviral therapy in a HIV-1/HIV-2/HBV co-infected patient.
-
Autorzy:
-
Cardoso M; Serviço de Doenças Infeciosas e Medicina Tropical, Hospital De Egas Moniz - Centro Hospitalar Lisboa Ocidental, 1349-019, Lisbon, Portugal. anamargaridacardoso_.
Vasconcelos J; Serviço de Doenças Infeciosas e Medicina Tropical, Hospital De Egas Moniz - Centro Hospitalar Lisboa Ocidental, 1349-019, Lisbon, Portugal.
Baptista T; Serviço de Doenças Infeciosas e Medicina Tropical, Hospital De Egas Moniz - Centro Hospitalar Lisboa Ocidental, 1349-019, Lisbon, Portugal.
Diogo I; Laboratório de Biologia Molecular, LMCBM, SPC.HEM - Centro Hospitalar Lisboa Ocidental, 1349-019, Lisbon, Portugal.
Gonçalves F; Laboratório de Biologia Molecular, LMCBM, SPC.HEM - Centro Hospitalar Lisboa Ocidental, 1349-019, Lisbon, Portugal.
Mansinho K; Serviço de Doenças Infeciosas e Medicina Tropical, Hospital De Egas Moniz - Centro Hospitalar Lisboa Ocidental, 1349-019, Lisbon, Portugal.
Gomes P; Laboratório de Biologia Molecular, LMCBM, SPC.HEM - Centro Hospitalar Lisboa Ocidental, 1349-019, Lisbon, Portugal.; Centro de Investigação Interdisciplinar Egas Moniz, CiiEM, ISCSEM, 2829-511, Almada, Portugal.
-
Źródło:
-
AIDS research and therapy [AIDS Res Ther] 2021 Oct 12; Vol. 18 (1), pp. 69. Date of Electronic Publication: 2021 Oct 12.
-
Typ publikacji:
-
Case Reports; Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [London] : BioMed Central, 2004-
-
MeSH Terms:
-
Coinfection*/drug therapy
HIV Infections*/drug therapy
HIV-1*/genetics
HIV-2/genetics ; Hepatitis B virus/genetics ; Humans ; Male
-
References:
-
AIDS. 2009 Jan 28;23(3):426-8. (PMID: 19114866)
N Engl J Med. 2012 Jul 19;367(3):224-32. (PMID: 22808957)
J Antimicrob Chemother. 2006 Apr;57(4):709-13. (PMID: 16464891)
Clin Infect Dis. 2011 Mar 15;52(6):780-7. (PMID: 21367732)
Clin Infect Dis. 2021 Feb 1;72(3):503-509. (PMID: 32227124)
-
Contributed Indexing:
-
Keywords: Antiretroviral therapy; Coinfection; HIV-1; HIV-2; Mutation; Resistance
-
Entry Date(s):
-
Date Created: 20211013 Date Completed: 20211022 Latest Revision: 20211022
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC8507372
-
DOI:
-
10.1186/s12981-021-00394-4
-
PMID:
-
34641890
-
Background: The current standard of care is to start antiretroviral therapy in all patients diagnosed with HIV-1, as for HIV-2 current DHHS guideline suggests ART for HIV-2 as soon as diagnosis is established, although this practice is not universal, for instance, in Portugal there are specific criteria to start treatment.
Case Presentation: We present a case of a man, chronically infected with HIV-1, HIV-2 and hepatitis B virus who developed resistance to HIV-2 while maintaining HIV-1 under control. 6 years after starting antiretroviral therapy he had his first virologic failure. We performed HIV-2 resistance tests that revealed high-grade resistance to all nucleoside reverse-transcriptase inhibitors except tenofovir and to all protease inhibitors except darunavir. After a decade of permanent poor adherence to therapy he developed resistance to both tenofovir and darunavir. We put together a new regiment with tenofovir alafenamide + emtricitabine + dolutegravir + maraviroc and nowadays he is with undetectable HIV-1 and HIV-2 viral loads.
Conclusions: This shows the importance of having access to HIV-2 viral load determination and HIV-2 resistance testing.
(© 2021. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.